Ligand Pharmaceuticals Incorporated
LGND
$104.97
$0.350.34%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 52.35% | 57.64% | 57.52% | -29.56% | -44.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.35% | 57.64% | 57.52% | -29.56% | -44.22% |
| Cost of Revenue | 1.87% | -9.90% | -3.09% | -14.71% | -76.86% |
| Gross Profit | 69.51% | 83.17% | 86.47% | -34.15% | 7.16% |
| SG&A Expenses | 60.11% | 67.00% | 56.14% | 0.88% | -48.63% |
| Depreciation & Amortization | -0.96% | 0.24% | -3.30% | -4.13% | -2.35% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.73% | 28.03% | 20.43% | -5.99% | -55.37% |
| Operating Income | 150.24% | 1,044.72% | 472.72% | -78.97% | 83.29% |
| Income Before Tax | -329.28% | 47.80% | -2,162.13% | 104.28% | -29.18% |
| Income Tax Expenses | -643.54% | 144.52% | -1,629.97% | 129.06% | -102.82% |
| Earnings from Continuing Operations | -270.93% | 30.19% | -2,366.86% | 97.50% | 225.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 100.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -270.93% | 30.19% | -2,366.86% | 105.34% | 204.02% |
| EBIT | 150.24% | 1,044.72% | 472.72% | -78.97% | 83.29% |
| EBITDA | 85.57% | 92.15% | 129.53% | -49.61% | 162.00% |
| EPS Basic | -257.35% | 34.12% | -2,271.57% | 97.59% | 200.59% |
| Normalized Basic EPS | 572.69% | -662.98% | -2,776.43% | -83.91% | 109.60% |
| EPS Diluted | -259.09% | 34.02% | -2,315.38% | 103.22% | 199.66% |
| Normalized Diluted EPS | 580.31% | -662.98% | -2,856.06% | -83.41% | 109.49% |
| Average Basic Shares Outstanding | 8.63% | 5.98% | 4.35% | 3.92% | 3.41% |
| Average Diluted Shares Outstanding | 7.34% | 5.98% | 1.68% | 0.82% | 4.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |